Core Insights - Nxera Pharma has achieved a significant development milestone in its collaboration with Eli Lilly, which is expected to result in a milestone payment in Q3 of the fiscal year ending December 2025 [1][2] - The collaboration, initiated in 2022, leverages Nxera's GPCR-focused drug design capabilities alongside Lilly's expertise in development and commercialization [2] - Nxera is eligible for up to US$694 million in development and commercial milestones, in addition to tiered royalties on global sales [3] Company Overview - Nxera Pharma is a biopharma company focused on developing specialty medicines for unmet medical needs, particularly in Japan and the broader APAC region [5] - The company has an extensive pipeline of over 30 active programs targeting areas such as neurology, metabolic diseases, and immunology, utilizing its proprietary NxWave™ discovery platform [6] - Nxera employs approximately 400 people across key locations including Tokyo, Osaka, London, Cambridge, Basel, and Seoul [7]

Core Insights - Nxera Pharma is a technology-powered biopharma company focused on developing specialty medicines to address unmet medical needs in Japan and globally [1][3]. Company Overview - Nxera Pharma has established a new-generation commercial business in Japan aimed at developing and commercializing innovative medicines for a large and growing market in the APAC region [2]. - The company employs approximately 400 professionals across key locations including Tokyo, Osaka, London, Cambridge, Basel, and Seoul, and is listed on the Tokyo Stock Exchange under the ticker 4565 [4]. Pipeline and Research - Nxera is advancing a pipeline of over 30 active programs from discovery to late clinical stages, utilizing its unique NxWave™ discovery platform [3]. - The pipeline focuses on addressing major unmet needs in rapidly growing medical fields such as neurology/neuropsychiatry, metabolic diseases, and immunology and inflammation [3]. Recent Developments - Neurocrine Biosciences presented new positive data from the Phase 2 study of NBI-1117568 for schizophrenia at the ASCP 2025 Annual Meeting, which is relevant to Nxera's interests in the neurology sector [1].

Core Insights - Nxera Pharma has made significant progress since its transformation from Sosei Heptares, aiming to lead biopharmaceutical innovation in Japan and globally [2][3] - The company anticipates 2025 to be a pivotal year with key data readouts from multiple clinical trials and new studies commencing [3] Operational Highlights - Neurocrine initiated a Phase 3 program for NBI-1117568 targeting schizophrenia, supported by positive Phase 2 data [5] - Nxera assigned rights for cenerimod to Viatris, receiving an upfront payment of US$10 million, with additional milestone and royalty potential [6] - An agreement was signed with Holling Bio-Pharma for the commercialization of daridorexant in Taiwan, with a potential launch in 2026 [6] - Clinical development plans for partnered muscarinic agonists include multiple Phase 2 and Phase 3 studies scheduled for 2025 [6] Financial Highlights - Revenue for Q1 2025 totaled JPY 6,644 million (US$43.5 million), an increase of JPY 2,033 million (US$12.5 million) year-over-year, primarily due to the launch of QUVIVIQ® and an R&D milestone event [11] - R&D expenses rose to JPY 3,808 million (US$25.0 million), reflecting increased investment and the impact of a weaker Yen [11] - Operating loss improved to JPY 2,193 million (US$14.4 million) from JPY 3,076 million (US$20.7 million) in the prior year [11] - Net loss decreased to JPY 760 million (US$5.0 million) from JPY 3,281 million (US$22.1 million) in the previous year [11] - Cash and cash equivalents as of 31 March 2025 were JPY 34,465 million (US$230.0 million), an increase of JPY 2,197 million (US$24.3 million) since the beginning of the year [11] Corporate Developments - New appointments to the Board of Directors include Ms. Naoko Shimura and Ms. Nicola Rabson as External Directors [6] - Mr. Kiyoshi Kaneko was appointed Chief Commercial Officer, and Ms. Mariko Nakafuji was promoted to Chief Legal Officer [11] Pipeline and Strategy - Nxera is advancing over 30 active programs from discovery to late clinical stages, focusing on neurology, metabolic diseases, and immunology [10][12] - The company aims to address major unmet needs in rapidly growing medical areas, leveraging its NxWave™ discovery platform [10][12]

Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces the appointment of Shinya Tsuzuki, as Head of Investor Relations. Mr. Tsuzuki will lead Nxera’s Investor Relations (IR) team in Japan and report to the Company’s Chief Financial Officer, Hironoshin Nomura. Mr. Tsuzuki joins Nxera from Mizuho Securities, where he served as a Senior Investment Analyst and has covered the pharmaceutical and biotechnology sector since 2018. During this time, ...